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Dear Editor,
we have read with great interest the work by 
pintarić et al.1 about the administration of propafenone 
in terminating atrioventricular nodal reentrant tachy-
cardia and atrioventricular reentrant tachycardia, 
where propafenone is presented as a safe and efficient 
antiarrhythmic drug. That inspired us to present an in-
teresting case which demonstrates how propafenone, 
if administered in a “wrong” clinical indication, is a 
potentially extremely harmful medication.
propafenone is an iC class antiarrhythmic agent 
which acts by blocking na+ channels and partially 
blocking ß-adrenergic receptors and Ca2+ channels. 
propafenone thus acts as a stabilizer of ion permeability 
of cardiac muscle cell membrane in cardiac pathologic 
conditions such as arrhythmias. propafenone prolongs 
both pr interval and Qrs complex on electrocardio-
grams, while it has no effect on Qt interval2,3. it is 
metabolized in the liver through cytochrome p-450 
2d6. patients are distinguished as “slow” and “fast” 
metabolizers. in “slow” metabolizers, better prophy-
lactic effect of propafenone was observed in prevent-
ing atrial fibrillation, but not in conversion to sinus 
rhythm. “fast” metabolizers have less ß-adrenergic 
blocking effect. maximum blood level of propafenone 
is achieved in 2-3 hours after its application. The main 
clinical indications for administration of propafenone 
are supraventricular tachycardias, including the ones 
occurring in wpw syndrome and atrial fibrillation 
in patients without structural heart disease. in gen-
eral, propafenone is not administered in cases of ven-
tricular rhythm disturbances, particularly in patients 
with preexisting structural heart disease. if given to 
patients with these cardiac pathologies, propafenone 
can induce proarrhythmic rather than antiarrhythmic 
effects with potentially detrimental consequences4,5.
An 80-year-old patient was admitted to the inten-
sive care unit due to electrocardiographically recorded 
atrial fibrillation with slow ventricular rate of up to 20 
beats per minute with rr pauses of up to 3.2 seconds 
(fig. 1), accompanied by dizziness and acute heart fail-
ure. The patient had a history of heart disease; he had 
survived two myocardial infarctions (fifteen and four 
years before) that consequentially led to the develop-
ment of ischemic cardiomyopathy with reduced systol-
ic function of the left ventricle (Ef 40% 2d simpson’s 
biplane analysis) and moderate mitral regurgitation. 
Thirteen years before, the patient underwent CABg x 
3 (LAd, rCA, om1-Vsm). recoronarography per-
formed in 2002 showed occluded bypasses on rCA 
and om1. Consequently, pCi of LAd-Vsm bypass 
was performed and one stent was implanted. The re-
sults of recoronarography performed two years before 
showed the bypass on LAd to be passable. in addition 
to the above cardiac pathologies, the patient also had 
long term arterial hypertension, dyslipidemia and sec-
ond stage chronic renal failure (gf ~70 mL/min/1.73 
m2). patient liver function was normal, his weight was 
82 kg. his regular medication treatment consisted of 
bisoprolol 2.5 mg per day plus lisinopril, amlodipine, 
atorvastatin, acetylsalicylic acid, isosorbide mononi-
trate, and he was in sinus rhythm. several days prior 
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to hospital admission, the patient experienced short-
term heart palpitations for which he was prescribed 
propafenone by his general practitioner. The patient 
had a history of taking propafenone. prior to his first 
heart attack, 15 years before, the patient had been 
administered propafenone for the same symptoms he 
was now experiencing and, at that time, the treatment 
resulted in excellent therapeutic results. This time, 
several days prior to hospital admission, the patient 
took propafenone in a dosage of 3x300 mg recom-
mended by his general practitioner. immediately after 
hospital admission, temporary cardiac electrostimula-
tor was implanted and the patient was dependent on 
cardiac electrostimulator for the following 12 hours. 
Afterwards, along with the patient’s sinus rhythm of 
60 to 80 beats per minute, we observed the occurrence 
of frequent, non-sustained, hemodynamically irrel-
evant, asymptomatic, morphologically different wide 
Fig. 1. Atrial fibrillation with slow ventricular rate.
Fig. 2. Different wide QRS complex tachycardias.
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Qrs complex tachycardias with the duration of up 
to maximum of 10 seconds (fig. 2). twelve hours af-
ter the onset of tachycardia, the patient was in stable 
sinus rhythm, without significant arrhythmias and 
pauses (fig. 3), thus we considered him clinically fully 
recovered. we observed no increase of cardioselective 
enzymes or any signs of acute coronary syndrome de-
velopment. Consequently, the patient was judged to 
be in excellent condition and was discharged.  
in the case described, the administration of 
propafenone to a patient with ischemic cardiomyopa-
thy along with significant comorbidity almost resulted 
in fatal outcome. fortunately, the patient received ap-
propriate clinical treatment on time. in the case de-
scribed, propafenone was improperly administered to 
a patient with structural heart disease and renal fail-
ure1-3. The improper administration was detected via 
symptomatic atrial fibrillation with slow ventricular 
rate, followed by propafenone induced arrhythmia4-6 
that was detected by non-sustained tachycardias with 
wide Qrs complexes. The observed tachycardias were 
asymptomatic and hemodynamically irrelevant. we 
would like to emphasize that general practitioner pre-
scribed propafenone based on the patient’s history of 
using propafenone with favorable outcome. 
in summary, the case we present here is another 
illustration that the administration of any antiar-
rhythmic drugs can have serious side effects5,6, and 
exceptional caution should be practiced when making 
Fig. 3. Stable sinus rhythm at discharge from the hospital.
a decision to prescribe them. furthermore, in order to 
avoid the potentially lethal side effects2,3, it is neces-
sary to detect arrhythmia/arrhythmias on electrocar-
diogram and thoroughly evaluate the patient’s disease 
history prior to the administration of any antiarrhyth-
mic drug.  
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